Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RR001 With Gemcitabine/Nab-paclitaxel in Locally Advanced Pancreatic Adenocarcinoma
2024-516019-26-00Phase 2Authorised
- Sponsor
- EIR Biotherapies
- Start
- Dec 2024
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RR001 in pancreatic adenocarcinoma (PDAC), sponsored by EIR Biotherapies. Primary endpoints: Safety of intratumoral RR001 with GEM/Nab-PTX and Maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Planned start Dec 2024; status: authorised.
02
Drugs
RR001
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516019-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516019-26-00.